natgillin/translations-raw huggingface dataset:
Lactose monohydrate Microcrystalline cellulose
6.1 Seznam pomožnih snovi jedro tablete laktoza monohidrat mikrokristalna celuloza kalcijev fosfat krospovidon magnezijev stearat obloga tablete laktoza monohidrat hipromeloza gliceriltriacetat titanov dioksid (E171)
Liver function and CK levels should be monitored.
Spremljati je treba delovanje jeter in vrednosti CK. Hemodializa verjetno ni učinkovita.
(ULN).
LDL.
As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C.
sodeluje tudi pri privzemu rosuvastatina v jetra membranski prenosnik OATP-C.
Paediatric use
Uporaba
However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, cyclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics.
Pri sočasni uporabi zaviralcev HMG-CoA-redukaze in gemfibrozila, fenofibrata, drugih fibratov in niacina
- in patients with myopathy.
bolnikov, ki so se zdravili s Crestorjem.
The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see Section 4.4
Odmerjanje pri bolnikih s predispozicijskimi dejavniki za miopatijo Priporočen začetni odmerek za bolnike s predispozicijskimi dejavniki za miopatijo je 5 mg (glejte poglavje 4.4 Posebna opozorila in previdnostni ukrepi).
Discontinuation or down titration of Crestor may result in a decrease in INR.
Ta se lahko zmanjša, če se zdravljenje s Crestorjem ustavi ali če se zmanjša njegov odmerek.
In a rat pre- and postnatal study, reproductive toxicity was evident from reduced litter sizes, litter weight and pup survival.
V pre in ponatalni raziskavi pri podganah so odkrili toksično delovanje na reproduktivno sposobnost:
Crestor-treated patients with all doses and in particular with doses > 20 mg.
Pri jemanju zdravila Crestor so pri bolnikih opazili učinke na skeletne mišice, npr. mialgijo, miopatijo in v redkih primerih tudi rabdomiolizo, pri vseh odmerkih, predvsem pa pri odmerkih > 20 mg.
- personal or family history of hereditary muscular disorders - previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate - alcohol abuse - age >70 years - situations where an increase in plasma levels may occur (see section 5.2 Pharmacokinetic properties)
- zmerna ledvična okvara (čistek kreatinina < 60 ml/min) - hipotiroidizem - osebna ali družinska anamneza dednih mišičnih obolenj - predhoden pojav toksičnih učinkov na mišice pri uporabi drugih zaviralcev HMG-CoA-reduktaze ali fibratov
There is no specific treatment in the event of overdose.
Specifičnega zdravljenja v primeru prevelikega odmerjanja ni. Zdravljenje je simptomatsko; zagotoviti je treba delovanje vitalnih organov.
Crestor, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis.
Tako kot druge zaviralce reduktaze HMG-CoA je treba tudi Crestor predpisati zelo previdno bolnikom,
Tablet coat
Filmsko obložena tableta.
Calcium phosphate Crospovidone
skupni holesterol holesterol HDL
The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance
Pri bolnikih z zmerno ledvično odpovedjo (očistek kreatinina < 60 ml/min) je priporočen začetni odmerek 5 mg. Odmerek 40 mg je kontraindiciran pri bolnikih z zmerno ledvično odpovedjo.Uporaba
Child-Pugh scores above 9.
N-demetilnega presnovka pa devetkrat večja.
Table 1 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb)
holesterol LDL/HDL, skupni holesterol/holesterol HDL, holesterol neHDL /HDL ter ApoB/ ApoA-I. Preglednica 1: Učinkovitost odmerka pri bolnikih s primarno hiperholesterolemijo (tipa IIa in
This dose can be continued for up to 13 weeks.
Ta odmerek se lahko jemlje do 13 tednov.
However, the following side effects are seen in between 1 and 10 patients in 1,000: irritability, nervousness, restlessness, insomnia, abnormal dreams, anxiety, migraine, lethargy (lack of energy), psychomotor hyperactivity (restlessness with increased activity), dizziness, somnolence (sleepiness), hypertension (high blood pressure), abdominal pain (stomach ache), dyspepsia (heartburn), mouth ulcers, dry mouth, hyperbilirubinaemia (high blood levels of bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes), dermatitis (skin inflammation), night sweats, pruritus (itching), rash, dry skin, pain in the extremities (arms and legs), symptoms of the menopause, asthenia (weakness), chest pain, glycosuria (sugar in the urine), proteinuria (protein in the urine), abnormal liver function tests and increased weight.
Vendar so bili pri 1 do 10 bolnikih izmed 1 000 opaženi naslednji neželeni učinki: razdražljivost, nervoza, nemirnost, nespečnost, nenavadne sanje, anksioznost, migrena, letargija (pomanjkanje energije), psihomotorična hiperaktivnost (nemirnost s povečano aktivnostjo), omotica, zaspanost, hipertenzija (visok krvni tlak), bolečine v trebuhu, dispepsija (zgaga), razjede v ustih, suha usta, hiperbilirubinemija (povečane ravni bilirubina v krvi, produkta razgradnje rdečih krvnih celic, ki lahko povzroči rumeno obarvanje kože in oči), dermatitis (vnetje kože), nočno potenje, pruritus (srbenje), izpuščaj, suha koža, bolečine v okončinah (rokah in nogah), znaki menopavze, astenija (šibkost), bolečina v prsih, glikosurija (sladkor v urinu), proteinurija (beljakovine v urinu), neobičajni rezultati testov delovanja jeter in povečana telesna masa.
‘Primary' means that the insomnia does not have any identified cause, including any medical, mental or environmental cause.
„Primarna“ pomeni, da nespečnost nima znanih vzrokov, ne kakršnih koli drugih zdravstvenih, duševnih ali okoljskih vzrokov.
It is available as white prolongedrelease tablets (2 mg).
Na voljo je v obliki belih tablet s podaljšanim sproščanjem (2 mg).
Patients should avoid alcohol before, during and after taking Circadin.
Bolniki se morajo izogibati alkoholu pred, med in po jemanju zdravila Circadin.
The European Commission granted a marketing authorisation valid throughout the European Union for Circadin to Rad Neurim Pharmaceuticals EEC Limited on 29 June 2007.
Evropska komisija je dovoljenje za promet z zdravilom Circadin, veljavno po vsej Evropski uniji, odobrila družbi Rad Neurim Pharmaceuticals EEC Limited dne 29. junija 2007.
When the results of all three studies were looked at together, 32% of the patients taking Circadin (86 out of 265) reported a significant improvement in symptoms after three weeks, compared with 19% of those taking placebo (51 out of 272).
Pri obravnavi rezultatov vseh treh študij skupaj se je izkazalo, da je 32 % bolnikov (86 od 265), ki so jemali zdravilo Circadin, po treh tednih občutilo bistveno izboljšanje simptomov, v primerjavi z 19 % bolnikov (51 od 272), ki so jemali placebo.
Circadin can cause drowsiness, so it should be used with caution if this could pose a risk to safety, including in people who need to drive or use machines.
Zdravilo Circadin lahko povzroči zaspanost, zato ga je treba uporabljati previdno, če lahko vpliva na varnost, med drugim tudi pri ljudeh, ki vozijo ali upravljajo stroje.
Other information about Circadin:
Druge informacije o zdravilu Circadin:
For more information about treatment with Circadin, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Circadin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Its levels in the blood normally increase after the onset of darkness and peak in the middle of the night.
Njegove ravni v krvi se navadno povečajo po nastopu teme in dosežejo vrh sredi noči.
The recommended dose of Circadin is one tablet a day, taken one to two hours before bedtime and after food.
Priporočeni odmerek zdravila Circadin je ena tableta na dan, eno do dve uri pred spanjem, in sicer po obroku.
This document is a summary of the European Public Assessment Report (EPAR) for Circadin.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Circadin.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Circadin.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Circadin, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Circadin should not be used in people who may be hypersensitive (allergic) to melatonin or any of the other ingredients.
Zdravila Circadin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) melatonin ali katero koli drugo sestavino zdravila.
The CHMP decided that, although Circadin has only been shown to have a small effect in a relatively small number of patients, its benefits are greater than its risks.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Circadin kljub temu, da je izkazalo majhen učinek pri razmeroma majhnem številu bolnikov, večje od z njim povezanih tveganj.
Circadin is used on its own for the short-term treatment of primary insomnia (poor quality of sleep) in patients aged 55 years or over.
Zdravilo Circadin se uporablja samostojno za kratkotrajno zdravljenje primarne nespečnosti (slabe kakovosti spanca) pri bolnikih, starih 55 let ali več.
Melatonin is involved in co-ordinating the body's sleep cycle by acting on cells in specific areas of the brain and helping to bring about sleep.
Melatonin sodeluje pri usklajevanju cikla spanja v telesu tako, da učinkuje na celice v določenih predelih možganov in spodbuja spanje.
What benefit has Circadin shown during the studies?
Kakšne koristi je zdravilo Circadin izkazalo med študijami?
The additional study showed that Circadin was more effective than placebo for at least 13 weeks.
Dodatna študija je pokazala, da je zdravilo Circadin učinkovitejše od placeba vsaj 13 tednov.
Circadin is a medicine that contains the active substance melatonin.
Circadin je zdravilo, ki vsebuje zdravilno učinkovino melatonin.
‘Prolonged-release' means that melatonin is released slowly from the tablet over a few hours.
„Podaljšano sproščanje“ pomeni, da se melatonin iz tablete sprošča počasi več ur.
Circadin was more effective than placebo at improving quality of sleep and the patients' ability to function normally on the following day.
Zdravilo Circadin je bilo pri izboljšanju kakovosti spanja in sposobnosti normalnega delovanja bolnikov naslednji dan učinkovitejše od placeba.
Side effects with Circadin are not common.
Neželeni učinki zdravila Circadin niso pogosti.
An additional study compared the effects of Circadin and placebo for up to six months.
V dodatni študiji so do šest mesecev primerjali učinke zdravila Circadin z učinki placeba.
The Committee recommended that Circadin be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Circadin odobri dovoljenje za promet.
Older people may produce less melatonin, leading to the development of insomnia.
Pri starejših ljudeh se tvori manj melatonina, kar vodi v pojav nespečnosti.
What is the risk associated with Circadin?
Kakšna tveganja so povezana z zdravilom Circadin?
Circadin has been compared with placebo (a dummy treatment) in three main studies involving a total of 681 patients aged over 55 years with primary insomnia.
Zdravilo Circadin so primerjali s placebom (zdravilom brez zdravilne učinkovine) v treh glavnih študijah s skupno 681 bolniki s primarno nespečnostjo, starimi nad 55 let.
The active substance in Circadin, melatonin, is a naturally occurring hormone, which is normally produced by a gland in the brain called the pineal gland.
Zdravilna učinkovina zdravila Circadin, melatonin, je naravno prisoten hormon, ki ga navadno proizvaja žleza v možganih, imenovana češerika (epifiza).
The main measure of effectiveness was the number of patients who reported a significant improvement in their quality of sleep and ability to function normally on the following day, after three weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so po treh tednih zdravljenja občutili bistveno izboljšanje kakovosti spanja in sposobnosti normalnega delovanja naslednji dan. Bolniki so resnost svojih simptomov ocenjevali s pomočjo standardnega vprašalnika.
By replacing the hormone, Circadin increases blood levels of melatonin, helping them to sleep.
Zdravilo Circadin z nadomeščanjem hormona poveča ravni melatonina v krvi, to pa olajša spanec.
Because Circadin tablets release melatonin slowly over a few hours, they mimic the natural production of melatonin in the body.
Ker se melatonin iz tablet zdravila Circadin počasi sprošča več ur, posnema naravno tvorbo melatonina v telesu.
For the full list of all side effects reported with Circadin, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Circadin, glejte navodilo za uporabo.
Why has Circadin been approved?
Zakaj je bilo zdravilo Circadin odobreno?
What is Circadin used for?
Za kaj se zdravilo Circadin uporablja?
The full EPAR for Circadin can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Circadin je na voljo tukaj.
How has Circadin been studied?
Kako je bilo zdravilo Circadin raziskano?
How does Circadin work?
Kako zdravilo Circadin deluje?
What is Circadin?
Kaj je zdravilo Circadin?
How is Circadin used?
Kako se zdravilo Circadin uporablja?
Date of latest renewal: 4 September 2014
Datum zadnjega podaljšanja: 4. september 2014
· Risk Management Plan (RMP) Not applicable.
· Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Swallow the tablet whole with a glass of water.
Tableto pogoltnite celo s kozarcem vode.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10 December 2009
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 10.december 2009
Most, but not all, of these patients had pre-existing cardiovascular risk factors.
Večina teh bolnikov, vendar ne vsi, je imela že obstoječe kardiovaskularne dejavnike tveganja.
- If you have problems with your heart.
- če imate težave s srcem.
It is not possible to determine whether these events are related directly to these factors or to other factors.
Ali so ti dogodki neposredno povezani s temi dejavniki ali s kakšnimi drugimi, ni mogoče ugotoviti.
Doses above 100 mg do not increase the efficacy.
Odmerki, večji od 100 mg, ne povečajo učinkovitosti.
Further information on clinical trials
Dodatne informacije o kliničnih preskušanjih
- If you have recently had a stroke or a heart attack, or if you have low blood pressure.
- če ste nedavno doživeli možgansko kap ali srčni infarkt ali če imate nizek krvni tlak.
See leaflet for further information.
Glejte navodilo za dodatne informacije.
- If you have certain rare inherited eye diseases (such as retinitis pigmentosa).
- če imate kakšno redko dedno očesno bolezen (npr. retinitis pigmentosa).
Because not all adverse reactions are reported the frequencies of these reactions cannot be reliably determined.
Ker niso prijavljeni vsi neželeni učinki, njihove pogostosti ni mogoče zanesljivo določiti.
- If you have a deformity of your penis or Peyronie's Disease.
- če imate deformacijo spolnega uda ali Peyroniejevo bolezen.
In clinical trials sildenafil was administered to more than 8000 patients aged 19-87.
V kliničnih preskušanjih je sildenafil dobilo več kot 8000 bolnikov, starih od 19 do 87 let.
Your doctor may decide on a lower dose for you.
Morda vam bo predpisal manjši odmerek.
Do not take Sildenafil Actavis with other medicines unless your doctor tells you that you can.
Zdravila Sildenafil Actavis ne jemljite skupaj z drugimi zdravili, razen če vam zdravnik pove, da ga lahko.
- Prolonged and sometimes painful erections - this occurs rarely (may affect up to 1 in 1,000 people)
· Dolgotrajne in včasih boleče erekcije - to se zgodi redko (pojavi se lahko pri največ 1 od 1000
Very common (may affect more than 1 in 10 people): headache.
Zelo pogost (pojavijo se lahko pri več kot 1 od 10 bolnikov) je glavobol.
The amount of time Sildenafil Actavis takes to work varies from person to person, but it normally takes between half an hour and one hour.
Čas do začetka delovanja zdravila Sildenafil Actavis se od človeka do človeka razlikuje, a po navadi traja od pol ure do eno uro.
Elderly Dosage adjustments are not required in elderly patients (≥ 65 years old).
Starejši Starejšim bolnikom odmerka ni treba prilagajati (≥ 65 let).
The mean absolute oral bioavailability is 41% (range 25-63%).
Povprečna absolutna peroralna biološka uporabnost je 41% (razpon: od 25 do 63%).
Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of sildenafil without sexual activity.
Številni dogodki so se zgodili kmalu po spolnem odnosu, nekateri pa kmalu po uporabi sildenafila, brez spolne dejavnosti.
Periodic Safety Update Reports
Redno posodobljena poročila o varnosti zdravila
You should not take Sildenafil Actavis more than once a day.
Zdravila Sildenafil Actavis ne smete vzeti več kot enkrat na dan.
It is not possible to determine whether these events were directly related to sildenafil.
Ni mogoče ugotoviti ali so bili ti dogodki neposredno povezani z zdravilom Sildenafil Actavis.
In order for Sildenafil Actavis to be effective, sexual stimulation is required.
Da bi bilo zdravilo Sildenafil Actavis učinkovito, je potrebna spolna stimulacija.
The safety profile of sildenafil is based on 9,570 patients in 74 double-blind placebo-controlled clinical studies.
Varnostni profil sildenafila temelji na podatkih 9570 bolnikov v 74 dvojno slepih s placebom kontroliranih kliničnih študijah.
- A sudden decrease or loss of vision - this occurs rarely
· Nenadno poslabšanje ali izguba vida - to se zgodi redko
Of note, most, but not all, of the men who experienced these side effects had heart problems before taking this medicine.
Omeniti je treba, da je večina moških, ne pa vsi, ki so imeli te neželene učinke imela težave s srcem že pred jemanjem tega zdravila.
In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Sildenafil Actavis and when you did.
V nujnih zdravstvenih primerih morate vašemu zdravniku, farmacevtu ali medicinski sestri povedati, da ste vzeli zdravilo Sildenafil Actavis in kdaj ste ga vzeli.
In controlled clinical trials, the discontinuation rate due to sildenafil was low and similar to placebo.
V kontroliranih kliničnih preskušanjih je bil delež prekinitev zaradi sildenafila majhen in podoben kot pri placebu.
These reports included dizziness and light-headedness, but not syncope.
V tej zvezi sta bili opisani omotica in rahla vrtoglavica, ne pa sinkopa.
Sildenafil Actavis with food and drink and alcohol Sildenafil Actavis can be taken with or without food.
Zdravilo Sildenafil Actavis skupaj s hrano in pijačo Zdravilo Sildenafil Actavis lahko vzamete s hrano ali brez nje.
If you feel that the effect of Sildenafil Actavis is too strong or too weak, talk to your doctor or pharmacist.
Če občutite, da je učinek zdravila Sildenafil Actavis premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing sildenafil in all subsets of the paediatric population for the treatment of erectile dysfunction.
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij za zdravilo Sildenafil Actavis za vse podskupine pediatrične populacije za zdravljenje erektilne disfunkcije.
- If you have a severe heart or liver problem.
- če imate hude težave s srcem ali jetri.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila : http://www.ema.europa.eu/.
Drinking alcohol can temporarily impair your ability to get an erection.
Pitje alkohola lahko prehodno poslabša sposobnost za erekcijo.
If you have an erection which lasts for more than 4 hours, you should contact a doctor immediately.
Če imate erekcijo, ki traja več kot 4 ure, se morate nemudoma posvetovati z zdravnikom.
You should not take more tablets than your doctor tells you to.
Ne vzemite več tablet, kot vam je naročil zdravnik.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000)).
V spodnji preglednici so vsi medicinsko pomembni neželeni učinki, ki so se v kliničnih preskušanjih pojavili z večjo incidenco kot pri placebu, navedeni po organskem sistemu in pogostnosti (zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100) in redki (≥1/10.000 do <1/1.000).
If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Sildenafil Actavis.
Če jemljete zdravila, imenovana zaviralci proteaz, npr. za zdravljenje okužbe s HIV, vam bo zdravnik sprva morda predpisal najmanjši odmerek (25 mg) zdravila Sildenafil Actavis.
Due to the nitrate component it has the potential to result in a serious interaction with sildenafil.
Zaradi nitratne sestavine je možno resno medsebojno učinkovanje s sildenafilom.
Pregnancy, breast-feeding and fertility Sildenafil Actavis is not indicated for use by women.
Nosečnost, dojenje in plodnost Zdravilo Sildenafil Actavis ni namenjeno za uporabo pri ženskah.
A double-blind, placebo-controlled exercise stress trial evaluated 144 patients with erectile dysfunction and chronic stable angina who regularly received anti-anginal medicinal products (except nitrates).
Dvojno slepa, s placebom kontrolirana študija z obremenitvenim testiranjem pri 144 bolnikih z erektilno disfunkcijo in kronično stabilno angino pektoris, ki so redno prejemali zdravila za zdravljenje angine pektoris (razen nitratov).
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in tmax of 60 minutes and a mean reduction in Cmax of 29%.
Če je sildenafil uporabljen s hrano, se stopnja absorpcije zmanjša s povprečno zapoznitvijo tmaks 60 minut in povprečnim zmanjšanjem Cmaks za 29%.
Sildenafil Actavis is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
Zdravilo Sildenafil Actavis je indicirano pri odraslih moških z erektilno disfunkcijo, tj. nezmožnostjo doseči ali ohraniti erekcijo penisa, ki bi zadoščala za zadovoljivo spolno dejavnost.
6.4 Special precautions for storage Store below 30°C.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30°C.
If you experience any of the following serious side effects stop taking Sildenafil Actavis and seek medical help immediately:
Če opazite katerega od naslednjih resnih neželenih učinkov, prenehajte jemati zdravilo Sildenafil Actavis in nemudoma poiščite zdravniško pomoč:
You should take Sildenafil Actavis about one hour before sexual activity.
Zdravilo Sildenafil Actavis vzemite približno eno uro pred predvideno spolno dejavnostjo.
If Sildenafil Actavis does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor.
Če vam zdravilo Sildenafil Actavis ne pomaga doseči erekcije ali dosežena erekcija ne traja dovolj dolgo za popoln spolni odnos, morate to povedati zdravniku.
At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone.
Po 24 urah je bila koncentracija sildenafila v plazmi še vedno približno 200 ng/mL v primerjavi s približno 5 ng/mL v primeru, ko je bil sildenafil uporabljen sam.